Tarik Asselah

Tarik Asselah's AcademicInfluence.com Rankings

Tarik Asselah

Computer Science

#8901

World Rank

#9357

Historical Rank

Artificial Intelligence

#4086

World Rank

#4144

Historical Rank

Database

#5894

World Rank

#6113

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Tarik Asselah Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tarik Asselah's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. (2015) (947)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. (2006) (560)
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. (2008) (553)
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients (2009) (483)
Fibrosis and disease progression in hepatitis C (2002) (446)
STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (379)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. (2018) (338)
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. (2010) (331)
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues (2007) (328)
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. (2008) (324)
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients (2012) (276)
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial (2015) (273)
HCV direct‐acting antiviral agents: the best interferon‐free combinations (2014) (243)
Faldaprevir and deleobuvir for HCV genotype 1 infection. (2013) (234)
COVID-19: Discovery, diagnostics and drug development (2020) (233)
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C (2007) (226)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. (2017) (218)
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. (2012) (207)
Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives (2016) (205)
Portal cavernoma‐associated cholangiopathy: A clinical and MR cholangiography coupled with MR portography imaging study (2003) (204)
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. (2006) (199)
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis (2017) (198)
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. (2012) (192)
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin (2010) (183)
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. (2009) (183)
Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin (2010) (179)
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. (2008) (175)
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. (2005) (169)
Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. (2005) (167)
New direct‐acting antivirals' combination for the treatment of chronic hepatitis C (2011) (161)
Long-term outcome of hepatitis C infection after bone marrow transplantation. (2004) (154)
Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C (2012) (141)
Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study (2002) (140)
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow (2012) (133)
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. (2011) (131)
Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. (2010) (130)
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study (2007) (128)
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C (2003) (126)
Gene expression and hepatitis C virus infection (2008) (122)
Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy (2006) (121)
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection (2016) (120)
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C (2010) (118)
Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure? (2018) (118)
Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial (2013) (116)
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension (2017) (108)
HBsAg quantification: useful for monitoring natural history and treatment outcome (2014) (104)
Genomics and HCV infection: progression of fibrosis and treatment response. (2012) (101)
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. (2016) (101)
Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. (2013) (98)
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (2006) (86)
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin (2008) (81)
Protease and polymerase inhibitors for the treatment of hepatitis C (2009) (79)
Consensus conference: Indications for Liver Transplantation, January 19 and 20, 2005, Lyon‐Palais Des Congrès (2006) (79)
MR cholangiography in primary sclerosing cholangitis. (1998) (77)
Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. (2005) (77)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. (2016) (77)
Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. (2013) (76)
Interferon free therapy with direct acting antivirals for HCV (2013) (76)
Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial (2013) (75)
O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY (2014) (73)
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. (2001) (72)
Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis (2002) (72)
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. (2007) (71)
Sofosbuvir for the treatment of hepatitis C virus (2014) (69)
Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development. (2020) (67)
101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2 (2012) (65)
The role of HBsAg quantification for monitoring natural history and treatment outcome (2013) (64)
Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir (2014) (64)
Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification (2019) (62)
Changes in autophagic response in patients with chronic hepatitis C virus infection. (2011) (62)
Towards HBV curative therapies (2018) (61)
Induction of mitochondrial biogenesis protects against acetaminophen hepatotoxicity. (2017) (61)
Caroli's Disease: A Magnetic Resonance Cholangiopancreatography Diagnosis (1998) (60)
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients (2015) (59)
Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. (2019) (58)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. (2016) (57)
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. (2007) (57)
Fibrosis and disease progression in hepatitis C (2002) (55)
Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms? (2015) (54)
1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL (2013) (54)
Breath-hold fast spin-echo MR imaging of Crohn's disease. (1998) (52)
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. (2019) (51)
Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up. (2001) (51)
ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis (2017) (48)
Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients (2016) (48)
Treatment of chronic hepatitis B (2005) (48)
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis (2018) (48)
Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody (2009) (47)
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. (2017) (47)
SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPY (2002) (47)
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis (2018) (46)
Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients (2005) (45)
O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection (2015) (45)
Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. (2014) (45)
Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3 (2018) (43)
Long‐term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal (2013) (43)
60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION (2011) (41)
Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy (2003) (40)
Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. (2010) (39)
MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C (2016) (38)
Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. (2017) (37)
Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. (2005) (37)
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. (2020) (36)
Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results (2013) (34)
[MR cholangiopancreatography]. (1997) (34)
Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients (2014) (34)
Improving performance of liver biopsy in fibrosis assessment. (2014) (34)
Allogeneic hematopoietic cell transplant in HCV-infected patients. (2008) (33)
Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. (2006) (32)
66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R (2011) (32)
725 QUANTITATIVE HBSAG: A NEW SPECIFIC MARKER FOR THE DIAGNOSIS OF HBSAG INACTIVE CARRIAGE (2010) (32)
LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension (2015) (31)
Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487 (2013) (31)
NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. (2011) (30)
Future treatments for hepatitis delta virus infection (2020) (30)
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. (2019) (29)
Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels (2002) (29)
Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C (2014) (29)
Optimal IFN‐free therapy in treatment‐naïve patients with HCV genotype 1 infection (2015) (29)
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older (2019) (28)
Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response. (2011) (28)
Mechanisms of non-response to antiviral treatment in chronic hepatitis C. (2011) (28)
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. (2002) (27)
miRNAs as Potential Biomarkers for Viral Hepatitis B and C (2020) (26)
Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. (2006) (26)
From HCV To HBV Cure (2017) (26)
Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4 (2018) (26)
IFNL3 (IL28B) polymorphism does not predict long‐term response to interferon therapy in HBeAg‐positive chronic hepatitis B patients (2014) (26)
Interferon therapy for chronic hepatitis B. (2007) (24)
The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
An update in the management of chronic hepatitis B. (2013) (24)
The current status of antiviral therapy of chronic hepatitis B. (2005) (24)
Significant gene expression differences in histologically “Normal” liver biopsies: Implications for control tissue (2008) (23)
Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data (2020) (23)
Multifactorial aetiology of hepatic infarction: a case report with literature review (2004) (23)
1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV (2010) (22)
P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (2015) (22)
French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. (2018) (22)
Sofosbuvir-based interferon-free therapy for patients with HCV infection. (2013) (22)
Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B (2015) (21)
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life (2021) (21)
1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. (2015) (20)
Prolonged cholestasis and ductopenia associated with tenoxicam. (2003) (20)
Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. (2006) (19)
ENDURANCE-4: Efficacy and Safety of ABT-493/ABT-530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection (2016) (19)
Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes (2018) (19)
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. (2015) (19)
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. (2022) (18)
Haemobilia causing acute pancreatitis after percutaneous liver biopsy: diagnosis by magnetic resonance cholangiopancreatography. (2001) (18)
HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. (2013) (18)
MR cholangiopancreatography: a promising new tool for diagnosing primary sclerosing cholangitis. (1997) (17)
A same day ‘test and treat’ model for chronic HCV and HBV infection: Results from two community‐based pilot studies in Egypt (2020) (17)
Endpoints and New Options for Treatment of Chronic Hepatitis D (2021) (16)
Acute hepatitis E with severe jaundice: report of three cases. (2007) (16)
Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity (2014) (16)
Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials (2019) (16)
SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients (2014) (16)
HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension (2016) (16)
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. (2013) (16)
Hepatitis C Virus: Current and Evolving Treatments for Genotype 4. (2015) (15)
Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine (2007) (15)
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? (2014) (15)
Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non‐neutrocytic ascites (2011) (14)
New therapies for hepatitis delta virus infection (2021) (14)
High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I) (2016) (14)
Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst (2004) (14)
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents (2016) (14)
Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort (2017) (13)
Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. (2020) (13)
Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C (2013) (13)
Prevalence of Hepatitis C Virus Infection in Patients Hospitalized for Hepatitis A (1999) (13)
[The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease. Presentation of 1 case and review of the literature]. (1998) (13)
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry (2018) (12)
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. (2015) (11)
SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules. (2010) (11)
Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis (2014) (11)
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study (2019) (10)
A revolution in HCV treatment with direct-acting antivirals: from non-response to eradication. (2012) (10)
High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study (2018) (9)
IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C (2015) (9)
Viral hepatitis: Impressive advances but still a long way to eradication of the disease (2014) (9)
Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease (2021) (9)
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis (2020) (9)
Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. (2006) (9)
Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease (2014) (9)
[Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. (2007) (9)
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. (2013) (9)
[Acute hemorrhagic colitis induced by glutaraldehyde after colonoscopy]. (1996) (9)
Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection (2016) (9)
A sprint to increase response to HCV treatment: expectancies but caution. (2011) (9)
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. (2021) (8)
Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients (2014) (8)
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
Realize the advance in HCV treatment, but remain cautious. (2011) (8)
532 SIGNIFICANT GENOTYPE-SPECIFIC ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LEVEL AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CHRONIC HEPATITIS B (2012) (8)
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response (2017) (8)
A dive into the complexity of type I interferon antiviral functions. (2012) (8)
Clevudine: a promising therapy for the treatment of chronic hepatitis B (2008) (8)
BILN 2061: a major step toward new therapeutic strategies in hepatitis C (2004) (8)
Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance (2021) (7)
Clevudine: a promising therapy for the treatment of chronic hepatitis B. (2008) (7)
Chronic Hepatitis C: Viral Clearance Several Months after Discontinuation of Therapy in Two Non-responders (2007) (7)
Triple therapy with boceprevir or telaprevir for prior HCV non-responders. (2012) (7)
GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888 (2016) (7)
Universal hepatitis B vaccination: The only way to eliminate hepatocellular carcinoma? (2015) (6)
Telbivudine therapy for chronic hepatitis B: A journey to identify super‐responders and to optimize treatment using the roadmap model (2017) (6)
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II) (2019) (6)
Steatosis in hepatitis C: What does it mean? (2003) (6)
Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. (2012) (6)
[618] OPTIMAL PRETREATMENT VIRAL LOAD CUT-OFF TO PREDICT TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON o-2b PLUS RIBAVIRIN (2007) (6)
Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies (2016) (6)
Unraveling the genetic predisposition of ribavirin-induced anaemia. (2010) (6)
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin (2016) (5)
Viral hepatitis: towards the eradication of HCV and a cure for HBV (2015) (5)
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study (2017) (5)
A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B (2016) (5)
1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS (2012) (5)
Abdominal pain in a cirrhotic patient with ascites. (1997) (5)
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (2021) (5)
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. (2022) (5)
Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection (2015) (5)
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available. (2015) (5)
468 Evidence for high rates of HCV and HBV related mortality in FRANCE: A large-scale national survey (2006) (5)
[Treatment of chronic hepatitis B]. (2004) (4)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study (2018) (4)
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings (2018) (4)
Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients (2019) (4)
P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1–6 HCV infection (2015) (4)
Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus (2022) (4)
A village without hepatitis C in Egypt: will micro-elimination lead to macro-elimination? (2018) (4)
Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. (2015) (4)
STARTVerso 1 : A randomized trial of faldaprevir plus pegylated interferon / ribavirin for chronic HCV genotype-1 infection q (2015) (4)
1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2 (2013) (4)
Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed (2020) (3)
Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naīve participants (2018) (3)
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. (2006) (3)
The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C (2018) (3)
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy (2014) (3)
Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection (2019) (3)
Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). (2021) (3)
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1) (2016) (3)
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. (2020) (3)
Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study (2022) (3)
IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
[21] INSULIN RESISTANCE IN 424 CHRONIC HEPATITIS C PATIENTS: ASSOCIATION WITH HCV REPLICATION AND ADVANCED FIBROSIS (2007) (3)
[Hepatitis B: clinical application of HBsAg quantification]. (2013) (3)
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis (2020) (3)
Treatment of viral hepatitis: a new era (2013) (3)
[Treatment of chronic hepatitis B]. (2011) (3)
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B (2018) (3)
571 More rapid drop of HCV RNA level under therapy and better sustained response rate in Egyptian patients versus non-Egyptian patients with HCV genotype 4 (2006) (2)
635 INSULIN RESISTANCE AND GEOGRAPHICAL ORIGIN ARE MAJOR PREDICTORS OF LIVER FIBROSIS AND RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN IN GENOTYPE 4 CHRONIC HEPATITIS C PATIENTS (2009) (2)
Iconography : Mechanisms of non-response to antiviral treatment in chronic hepatitis C (2011) (2)
Editorial: HBV cure—the quest for biomarkers to predict off‐treatment sustained response (2021) (2)
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies (2020) (2)
Corrigendum to “Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B” [J Hepatol 43 (2005) 920–923] (2006) (2)
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
854 BACTERIAL DNA IS RARELY DETECTED IN THE SERUM AND THE ASCITIC FLUID OF NONINFECTED OUTPATIENTS WITH CIRRHOSIS AND ASCITES TREATED BY PARACENTESIS (2010) (2)
Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction (2014) (2)
782 HEPATIC MIRNA SIGNATURE PREDICTING SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (2011) (2)
Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings (2022) (2)
P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE (2014) (2)
529 WEEK 12 HBSAG TITER DECLINE IS PREDICTIVE OF SVR IN CHRONIC HEPATITIS B PATIENTS RECEIVING PEGYLATED INTERFERON PLUS TENOFOVIR COMBINATION THERAPY (2012) (2)
IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
THU-111-High efficacy and safety of the combination HCV regimen elbasvir and grazoprevir for 8 weeks in treatment-naive non-severe fibrosis HCVGT1b-infected patients: Final results of the STREAGER study (2019) (2)
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France (2020) (2)
HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management (2021) (2)
Integrated Analysis of SOF + RBV or LDV/SOF for the Treatment of Genotype 4 Chronic HCV Infection (2016) (2)
Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. (2006) (2)
Towards the eradication of hepatitis C virus (2012) (2)
Interferon stimulated genes and hepatitis C virus infection. (2012) (2)
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis (2021) (2)
Hypervariable region 1 quasispecies in chronic hepatitis C patients: influence of genotype (2001) (1)
Long-Term Risk of Hepatocellular Carcinoma during Follow-Up of Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2016) (1)
[Orbital metastasis of hepatocellular carcinoma: efficacy of local radiotherapy]. (1996) (1)
1209 IMPACT OF EARLY RESPONSE DEFINITIONS ON DURATION AND OUTCOME OF TREATMENT WITH BI201335 PLUS PR (2012) (1)
M1891 Quantitative HBsAg: A New Specific Marker for the Diagnosis of HBsAg Inactive Carriage (2010) (1)
844 IMPACT OF ANTIVIRAL THERAPY ON SURVIVAL IN PATIENTS WITH ADVANCED FIBROSIS – EXPERIENCE OF BEAUJON HOSPITAL 2000 TO 2010 (2013) (1)
Mesenteric obesity in Crohn's disease (CD) (1998) (1)
Analysis of AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir (2018) (1)
Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus (2022) (1)
THU-112-Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies (2019) (1)
Serum tumor necrosis factor level in chronic hepatitis C (2001) (1)
Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
[Chronic hepatitis C: what to do if the first treatment failed?]. (2002) (1)
[What does chronic hepatitis C steatosis mean?]. (2003) (1)
Profiling of routine serum parameters and AFP evolution in cirrhosis following HCVeradication for stratification of HCC risk: a trajectory clustering analysis from the ANRS CO12 CirVir cohort (2020) (1)
Ledipasvir/Sofosbuvir With or Without Ribavirin for the Treatment of Patients With Genotype 2-6 Chronic HCV Infection: Summary Results From Four Phase II Studies: 2071 (2015) (1)
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents (2016) (1)
781 INCIDENCE AND PREDICTORS OF HCC IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS AND NON RESPONDING TO PEGINTERFERON AND RIBAVIRIN THERAPY (2009) (1)
High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes (2018) (1)
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon (2014) (1)
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I) (2016) (1)
COVID‐19‐associated hepatic artery pseudoaneurysms (2022) (1)
1058 INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C (2010) (1)
Nucleic acid polymers as « HBsAg-targeting » agents: high efficacy but more trials are needed! (2020) (1)
684 LIVER GENE EXPRESSION SIGNATURE TO PREDICT RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C (2010) (1)
777 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH A LOWER RISK OF COMPLICATIONS AND HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HCV RELATED CIRRHOSIS (2008) (1)
783 DIFFERENTIAL LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C PATIENTS AT EARLY STAGES OF LIVER FIBROSIS (2011) (1)
Management of chronic hepatitis C. (2007) (1)
Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis (2022) (1)
447 IL28B POLYMORPHISM IS NOT ASSOCIATED WITH RESPONSE TO CONVENTIONAL INTERFERON TREATMENT AND HBSAG SEROCLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS (2012) (1)
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study) (2016) (1)
756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection (2016) (1)
Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort) (2022) (1)
573 Long-term outcome of hepatitis C infection after bone marrow transplantation (2003) (1)
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (1)
1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY (2013) (1)
390 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY IS SIMILAR IN HEPATITIS B AND HEPATITIS C PATIENTS (2010) (1)
P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: a multivariate analysis (2015) (1)
Interferon-stimulated gene 15: a dual activity during hepatitis C virus infection (2010) (1)
EASL‐ALEH 2015 algorithm for the use of transient elastography in treatment‐naive patients with hepatitis B: An independent validation (2021) (1)
Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohort. (2014) (1)
NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS B VIRUS. (2021) (1)
754 QUASISPECIES ANALYSIS OF HBV STRAINS ISOLATED FROM CHRONIC HEPATITIS B PATIENTS TREATED WITH PEG-INTERFERON+ TENOFOVIR THERAPY (2013) (1)
P776 REDUCTION OF MIR-122 IN IFNL3 CT+TT CARRIERS AND DURING PROGRESSION OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (2014) (1)
Baseline HBsAg and HBcrAg Titers Allow Peginterferon Based “Precision Medicine” in Hbeag-Negative Chronic Hepatitis B (2016) (1)
Long-Term Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2018) (1)
Phase III, Multicenter Open-Label Study to Investigate the Efficacy of Elbasvir and Grazoprevir Fixed-Dose Combination for Eight Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with Non-Severe Fibrosis (2020) (1)
Treatment of chronic hepatitis B: an update (2005) (0)
Mitochondrial DNA damage and mitochondrial dysfunction in patients with chronic hepatitis B (2020) (0)
820 A FOUR GENE MOLECULAR SIGNATURE IS BETTER THAN IL28B POLYMORPHISM TO PREDICT TREATMENT RESPONSE TO PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C (2012) (0)
P738 NO CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN FALDAPREVIR AND PEGYLATED INTERFERON a-2a PLUS RIBAVIRIN IN HCV-INFECTED PATIENTS: PHARMACOKINETIC ANALYSES FROM TWO PHASE II STUDIES (2014) (0)
PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
Predictors of progression of liver disease in chronic hepatitis C patients with minimal fibrosis: kinetic of serum tumor necrosis factor and transforming growth factor serum levels (2002) (0)
An Easy-to-Use Baseline Score to Predict Response to Peginterferon Alfa-2a in Patients with Chronic Hepatitis B in Resource-Limited Settings (2016) (0)
1103 A 4 SERUM PROTEIN SIGNATURE FOR THE DIAGNOSIS OF MILD FIBROSIS IN CHRONIC HEPATITIS C (HEPACHRONIX STUDY) (2013) (0)
Liver steatosis is not associated with fibrosis in patients with chronic HCV infection (2003) (0)
Congrès annuel de l’American association for the study of liver disease (AASLD), San Francisco, 2005 (2006) (0)
P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION (2014) (0)
Acknowledgement to our reviewers (2006) (0)
Reply: (2008) (0)
P.232 Egyptian patients have better sustained response and more rapid drop of HCV RNA level than non-Egyptian patients with HCV genotype 4 (2006) (0)
[526] ROLE OF HIV COINFECTION IN MORTALITY RELATED TO HEPATITIS C AND HEPATITIS B IN FRANCE (2007) (0)
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (2021) (0)
Sa1029 An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, Bi 207127 and Ribavirin in the Sound-C2 Study (2013) (0)
Cytokine-chemokine signiture and severity of chronic hepatitis C (2003) (0)
Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study. (2022) (0)
M1898 In Vitro Susceptibility of HBV Strains Isolated From HBV Patients With Primary Nonresponse to Adefovir (2010) (0)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C (2008) (0)
Assessment of Baveno VI and expanded Baveno VI criteria for screening and follow-up of all-size esophageal varices in patients with compensated viral cirrhosis (ANRS/CO12 CirVir cohort) (2020) (0)
Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study (2016) (0)
[Chronic hepatitis B: which patients should be treated and how?]. (2005) (0)
323 Two types of histologically normal liver can have marked difference in gene expression profiles: Importance of an adequate normal tissue control in gene expression studies (2006) (0)
Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection (2023) (0)
Virus-Infected Cirrhotic Patients in Treatment-Experienced Hepatitis C Pegylated Interferon during Triple Therapy Effectiveness of Telaprevir , Boceprevir , and Modeling To Estimate the Antiviral Using Pharmacokinetic and Viral Kinetic (2014) (0)
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection (2023) (0)
A Microrna-Based Diagnostic Tool to Predict Advanced Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B and C (2016) (0)
HEPATITIS Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis (2003) (0)
Chronic hepatitis B (2012) (0)
[MRI cholangiopancreatography]. (1998) (0)
HBV REPLICATION CYCLE AND THERAPEUTIC TARGETS (0)
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors (2022) (0)
Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial (2022) (0)
Reply (2011) (0)
1149 REDUCTION OF mir-122 EXPRESSION IN IL28B CT/TT CHRONIC HEPATITIS C PATIENTS WHO FAILED TO PEGYLATED-INTERFERON PLUS RIBAVIRIN TREATMENT (2013) (0)
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (0)
Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens (2022) (0)
P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC) (2015) (0)
Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study (2022) (0)
778 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH REVERSIBILITY OF CIRRHOSIS IN CHRONIC HEPATITIS C PATIENTS (2008) (0)
AJG-21-0820 253..263 (0)
IDDF2019-ABS-0211 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies (2019) (0)
IDDF2018-ABS-0067 Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study (2018) (0)
Risk Factors and Characteristics of Hepatocellular Carcinoma Occuring in HCV Cirrhotic Patients after Sustained Virological Response (2016) (0)
834 REDUCTION OF MIR-122 EXPRESSION IS ASSOCIATED WITH IL28B RS12979860 TT POLYMORPHISM AND IS INDEPENDENT OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C (2012) (0)
THU-194-Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies (2019) (0)
Precore and Basal Core Promoter Mutants Improve the Diagnostic Performance of Fibroscan® or Fibrotest® to Predict Significant Fibrosis in Chronic Hepatitis B Patients (2016) (0)
Therapeutic options for chronic hepatitis B in 2013 (2013) (0)
Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis (2018) (0)
P0626 : The analysis of the expression of A2M, COL1A1, MMP2 and CHI3L identifies significant fibrosis in patients with chronic hepatitis B (2015) (0)
503 High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) (2016) (0)
Mo1389 - Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The Endurance-5,6 Study (2018) (0)
Su1062 Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon α-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12 (2014) (0)
P725 IMPACT OF THE rs8099917 SNP ON SVR12 IN PATIENTS WITH HCV GT-1 INFECTION TREATED WITH FALDAPREVIR, DELEOBUVIR AND RIBAVIRIN (2014) (0)
RECENT ADVANCES IN CLINICAL PRACTICE STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (0)
Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies (2014) (0)
Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients (2022) (0)
824 IMPACT OF IL28B GENOTYPE ON HCV TREATMENT DECISION IN A LARGE FRENCH COHORT (2013) (0)
Current Management of Patients with HCV Genotype 4 (2021) (0)
410 Gene expression profiling of liver fibrosis in patients with hepatitis C virus chronic infection using a large scale real-time RT-PCR approach (2003) (0)
[Hepatitis E: vaccine in a near future?]. (2008) (0)
Value Of Treating All Liver Fibrosis Stages To Reach Elimination Of Diagnosed Chronic Hepatitis C: A Modelling Approach In France (2017) (0)
Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients (2019) (0)
Abdominal pain in a 22 year old woman (2000) (0)
cirrhosis at the edge of decompensation: Will ABT-450/r, and ribavirin solve the need for treatment? (2014) (0)
1135 INCREASED ALANINE AMINOTRANSFERASE ACTIVITY AND ACUTE LIVER FAILURE DURING ACUTE INFECTION BY THE NON HEPATOTROPIC CHIKUNGUNYA VIRUS: CRITICAL ROLE OF PARACETAMOL (2010) (0)
835 GLOBAL ANALYSIS OF LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C LEADING TO A SIGNATURE TO PREDICT RESPONSE TO TREATMENT (2012) (0)
P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
T1958 Liver Gene Expression Signature of Mild Fibrosis in Chronic Hepatitis C (2010) (0)
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon / Ribavirin ( PR ) in Treatment-Na ï ve Patients with Hepatitis C Virus ( HCV ) Genotype 1 ( GT 1 ) (2016) (0)
640 IN VIVO LIVER ENDOPLASMIC RETICULUM STRESS IN CHRONIC HEPATITIS C (2010) (0)
Abstracts: 2013 American College of Clinical Pharmacology Annual Meeting. (2013) (0)
Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries. (2023) (0)
Prognostic value of genotyping in hepatocellular carcinoma: a systematic review. (2023) (0)
Current Management of Patients with HCV Genotype 1 (2021) (0)
597 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non responders to standard combination therapy (2006) (0)
HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015 (2015) (0)
Reply to “Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C”: HCV genotype 4 infection: A major medical need (2012) (0)
P0860 : The impact of interferon-free regimens on employment rate during treatment in patients with chronic hepatitis C (2015) (0)
SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort (2019) (0)
[Genetic variability of the hepatitis C virus: clinical implications]. (2000) (0)
Efficacy of peginterferon ALFA-2A (40KD) (PEGASYS) plud ribavirin for 24 weeks in genotype 1 patients with chronic hepatitis C followed by mono or combination therapy for 22 weeks: Preliminary analysis of an open, multicenter, randomized trial (2003) (0)
Pretherapeutic Evaluation of the Patients with HCV Infection (2019) (0)
Treatment of chronic hepatitis B (2005) (0)
Novel α-2-macroglobulin cleaved fragments as biomarkers of early liver fibrosis in patients with chronic hepatitis C (2015) (0)
P0656 : Add on peginterferon to adefovir enhances HBsAg loss in inactive HBV carriers (2015) (0)
Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis (2022) (0)
Shortening overall treatment to 12 weeks of Simeprevir (SMV) plus PEG-IFN/RBV in treatment-naïve chronic Hepatitis C (CHC) Genotype 1 patients: assessment of baseline and week 2 on-treatment predictors of SVR (2015) (0)
Treatment of chronic hepatitis c. (2004) (0)
Healthcare resource utilization in treatment-naïve patients with compensated cirrhosis receiving 8-weeks’ glecaprevir/ pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review (2022) (0)
Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta (2022) (0)
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta. (2023) (0)
[Treatment of chronic hepatitis B]. (2006) (0)
Is Interferon a Valuable First‐Line Therapy for HBeAg‐Positive HBV? (2010) (0)
[Delta hepatitis: Epidemiology, diagnostic, natural history and treatment]. (2021) (0)
[Treatment "à la carte" of chronic hepatitis B]. (2008) (0)
316 IN VIVO ENDOPLASMIC RETICULUM STRESS IN PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
[Treatment of chronic hepatitis B]. (2004) (0)
P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS (2014) (0)
Sofosbuvir + simeprevir +/-ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort. (2016) (0)
Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data (2023) (0)
Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study (2022) (0)
Hepatitis C triple therapy in the near future: New opportunities to cure (2014) (0)
Shortening overall treatment to 12 weeks of SIMEPREVIR plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis (2015) (0)
128 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN) TO IDENTIFY PATIENTS ELIGIBLE FOR ANTIVIRAL TREATMENT IN CHRONIC HEPATITIS B (2011) (0)
Hypervariable region 1 (HVR 1) quasispecies outcome in patients with chronic hepatitis C (2001) (0)
Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study (2022) (0)
[136] CHIKUNGUNYA VIRUS EPIDEMIC IN SAINT BENOIT, LA REUNION ISLAND: AN EPIDEMIOLOGIC STUDY OF A CLUSTER OF ACUTE LIVER DISEASES (2007) (0)
Su1427 Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I) (2016) (0)
Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection: 868 (2017) (0)
83 ALTERED EXPRESSION OF MICRORNAS (MIRNAS) IN LIVERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir plus /-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials (2015) (0)
388 Gene expression profiling of liver fibrosis in patients with chronic HCV infection using a large scale real-time RT-PCR approach (2004) (0)
IFNL3 expression and response to treatment: behind the HCV tricks. (2014) (0)
Diagnostic performance of a new algorithm combining simple, non-invasive and inexpensive tests for predicting the presence of liver severe fibrosis and cirrhosis in patients with chronic hepatitis B (2020) (0)
P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4) (2015) (0)
P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES (2014) (0)
PTH-137 Safety and efficacy of simeprevir (SMV) plus PEG-IFN/RBV in treatment-naÏve chronic hepatitis c genotype 1 patients eligible for 12 weeks of treatment (2015) (0)
Open‐label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1‐infected patients who failed placebo plus peginterferon and ribavirin (2016) (0)
P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIAL (2014) (0)
T2000 Liver Gene Expression Signature to Predict Response to Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C (2010) (0)
Chapter 20. Treatment of Chronic Hepatitis B (2007) (0)
391 ABSENCE OF INFLUENCE OF METABOLIC FACTORS ON DIAGNOSTIC PERFORMANCE OF LIVER STIFFNESS MEASUREMENT IN CHRONIC HEPATITIS B AND C (2010) (0)
The Changing Demographics of Hepatitis B Virus Infection. (2021) (0)
Clinical Pharmacology in Drug Development Offi cial Publication of the American College of Clinical Pharmacology (2013) (0)
Hepatitis C Treatment: An Existing Ongoing Revolution (2015) (0)
Title page (2016) (0)
P0657 : Adding tenofovir to Pegylated Interferon enhances end of treatment HBsAg loss in HBeAg negative chronic hepatitis B patients (2015) (0)
Easl-Aleh Guidelines for the Non-Invasive Evaluation of Liver Disease Severity in Chronic Hepatitis B: An Independent Validation (2016) (0)
P.245 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non-responders to standard combination therapy (2006) (0)
O.139 Two types of histologically normal liver can have different gene expression patterns: The importance of an adequate normal tissue control in gene expression studies (2006) (0)
P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12 (2014) (0)
Risks of Liver Complications after a Long-Term Follow-Up in Patients with Chronic Hepatitis C with Sustained Virologic Response (2016) (0)
Distribution of patients by guideline-defined disease phase and/ or grey zones in B-Clear, an international multicentre clinical trial (2022) (0)
P0523 : Modification of expression of MIR-20A, MIR-92A and MIR-122 during fibrosis in patients with chronic hepatitis C (2015) (0)
Performance of Radiomics in Microvascular Invasion Risk Stratification and Prognostic Assessment in Hepatocellular Carcinoma: A Meta-Analysis (2023) (0)
Hepatitis B virus Resistance to Antivirals : Diagnosis and Management (2011) (0)
Peginterferon, Ribavirin and Anti-viral Triple Therapy (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tarik Asselah?

Tarik Asselah is affiliated with the following schools:

Université Paris Cité
Learning Planet Institute
Queen Mary University of London
Paris Diderot University

Tarik Asselah's Academic­Influence.com Rankings

Why Is Tarik Asselah Influential?

Tarik Asselah's Published Works

Published Works

What Schools Are Affiliated With Tarik Asselah?

Tarik Asselah's AcademicInfluence.com Rankings